Flipping antimicrobial peptides in the exit tunnel of the bacterial ribosome.
Antimicrobial peptides just got a plot twist. Researchers have found that tiny structural tweaks can flip how proline-rich antimicrobial peptides (PrAMPs) work inside bacterial cells. Instead of a single mechanism, these peptides can switch up their attack—depending on which way they bind in the ribosome’s exit tunnel.
Nat Commun
by Huang W, Berger MJ, Safdari HA et al.
“Flipping antimicrobial peptides in the exit tunnel of the bacterial ribosome. Huang W(#)(1)(2)(3), Berger MJ(#)(4), Safdari HA(4), Klepacki D(1)(2), Paternoga H(4), Baliga C(1)(2)(5), Wilson DN(6), Vázquez-Laslop N(7)(8), Mankin AS(9)(10). Author information: (1)Department for Pharmaceutical Sciences, University of Illinois, Chicago, IL, USA. (2)Center for Biomolecular Sciences, University of Illinois, Chicago, IL, USA. (3)College of Agronomy and Biotechnology, Yunnan Agricultural University, Kunming, China. (4)Institute for Biochemistry and Molecular Biology, University of Hamburg, Hamburg, Germany. (5)Faculty of Life and Allied Health Sciences, Department of Biotechnology, M. S. Ramaiah University of Applied Sciences, Bangalore, India. (6)Institute for Biochemistry and Molecular Biology, University of Hamburg, Hamburg, Germany. daniel.wilson@uni-hamburg.de. (7)Department for Pharmaceutical Sciences, University of Illinois, Chicago, IL, USA. nvazquez@uic.edu. (8)Center for Biomolecular Sciences, University of Illinois, Chicago, IL, USA. nvazquez@uic.edu. (9)Department for Pharmaceutical Sciences, University of Illinois, Chicago, IL, USA. shura@uic.edu. (10)Center for Biomolecular Sciences, University of Illinois, Chicago, IL, USA. shura@uic.edu. (#)Contributed equally Proline-rich antimicrobial peptides (PrAMPs) kill bacteria by binding in the ribosomal nascent peptide exit tunnel. Type II PrAMPs bind in an orientation matching that of the nascent protein, trap the release factors and arrest ribosomes at stop codons. Conversely, Type I PrAMPs bind in an opposite orientation: their N-terminus invades the peptidyl transferase center arresting translation at start codons. Here, by mining the genome databases, we identify a number of PrAMPs with high sequence similarity to the Type II PrAMP Drosocin. Notably, many of the new PrAMPs do not stall ribosomes at stop codons, but act as Type I PrAMPs arresting translation at start codons. Structural analysis shows that such peptides bind with a Type I orientation. Minimal alterations in the peptide structure can flip the orientation of the PrAMP in the exit tunnel, switching the mechanism of translation inhibition. Altering the mode of binding and action of a PrAMP by only few mutations could be exploited by the host to combat newly emerging bacterial pathogens. © 2026. The Author(s). Conflict of interest statement: Competing interests: The authors declare no competing interests.”
Here’s the scoop: PrAMPs target the ribosome, the core protein factory of bacteria. Type II PrAMPs (like Drosocin) latch on in one direction. They jam the bacterial machinery at stop codons by trapping release factors, freezing translation right at the end of the line. Type I PrAMPs, on the other hand, bind in the opposite orientation. Their N-terminus buries into the peptidyl transferase center, halting protein synthesis right at the start codon.
The team dug into genome databases and found a bunch of new PrAMPs closely related to Drosocin. Some didn’t follow the classic Type II script—they acted like Type I PrAMPs instead, blocking translation at the start. Structural studies nailed down the reason: a simple flip in binding orientation.
Key takeaway: Minor edits in a PrAMP’s sequence can force it to flip and change its mode of attack. This means bacteria face a moving target, and hosts can evolve new defenses with just a few mutations.
Flip the orientation, flip the function—a small change in peptide sequence, a big change in mechanism
This opens up new ideas for designing custom antimicrobial peptides that can adapt quickly
For anyone tracking antimicrobial peptide research, this is a reminder: function isn’t locked in. Sequence tweaks can unlock new strategies for fighting bacteria. Want to see which vendors supply research peptides or sort out your next experiment? Check the vendor directory.
Flipping the script on bacterial ribosomes could be the next move in antimicrobial research.
Related Reading
The STRIDE Trial and Semaglutide: Implications for Clinical Vascular Practice.
News · J Med ChemStructure-Based Adaptation of a SARS-CoV-2 Neutralizing Peptide to New Virus Variants.
News · J Nucl MedCombining an α(v)β(6)-Targeted (177)Lu-Based Peptide Receptor Radionuclide Therapy with Olaparib to Boost Therapeutic Efficacy in Pancreatic Cancer.
For Research Use Only
All content published on Pushing Peptides is intended for educational and informational purposes only. The information provided is not intended as medical advice, diagnosis, or treatment. Peptides discussed in this article are research compounds and are not approved for human therapeutic use by the FDA or any other regulatory agency. All studies referenced involve animal models or in vitro research unless otherwise stated. Consult a qualified healthcare professional before making any decisions related to your health. Pushing Peptides does not sell peptides — we are a vendor directory and educational resource.